Cambridge Investment Research Advisors’s First Trust NYSE Arca Biotechnology Index Fund FBT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$10.5M Buy
52,054
+13,893
+36% +$2.87M 0.03% 602
2025
Q4
$7.88M Buy
38,161
+1,184
+3% +$237K 0.02% 688
2025
Q3
$6.63M Buy
36,977
+1,639
+5% +$279K 0.02% 760
2025
Q2
$5.7M Buy
35,338
+4,277
+14% +$681K 0.02% 783
2025
Q1
$5.28M Sell
31,061
-346
-1% -$60.1K 0.02% 776
2024
Q4
$5.22M Buy
31,407
+6,482
+26% +$1.11M 0.02% 787
2024
Q3
$4.29M Buy
24,925
+7,936
+47% +$1.31M 0.01% 884
2024
Q2
$2.62M Sell
16,989
-7,823
-32% -$1.17M 0.01% 1109
2024
Q1
$3.81M Sell
24,812
-140
-0.6% -$21.3K 0.01% 905
2023
Q4
$3.94M Sell
24,952
-4,408
-15% -$633K 0.02% 826
2023
Q3
$4.3M Sell
29,360
-2,598
-8% -$396K 0.02% 725
2023
Q2
$4.89M Buy
31,958
+1,750
+6% +$273K 0.02% 672
2023
Q1
$4.68M Sell
30,208
-1,418
-4% -$223K 0.02% 661
2022
Q4
$4.88M Buy
31,626
+3,571
+13% +$527K 0.03% 616
2022
Q3
$3.7M Buy
28,055
+1,036
+4% +$145K 0.02% 701
2022
Q2
$3.66M Sell
27,019
-446
-2% -$61.5K 0.02% 742
2022
Q1
$4.1M Sell
27,465
-5,546
-17% -$820K 0.02% 732
2021
Q4
$5.35M Buy
33,011
+2,190
+7% +$354K 0.02% 615
2021
Q3
$5.12M Buy
30,821
+124
+0.4% +$21.2K 0.03% 596
2021
Q2
$5.3M Sell
30,697
-1,440
-4% -$238K 0.03% 590
2021
Q1
$5.16M Sell
32,137
-5,388
-14% -$923K 0.03% 549
2020
Q4
$6.3M Sell
37,525
-6,090
-14% -$988K 0.04% 438
2020
Q3
$6.86M Sell
43,615
-9,810
-18% -$1.6M 0.05% 366
2020
Q2
$8.96M Buy
53,425
+11,457
+27% +$1.8M 0.07% 276
2020
Q1
$5.5M Buy
41,968
+2,690
+7% +$383K 0.05% 337
2019
Q4
$5.84M Buy
39,278
+12,200
+45% +$1.68M 0.05% 405
2019
Q3
$3.35M Buy
27,078
+4,539
+20% +$604K 0.03% 563
2019
Q2
$3.17M Sell
22,539
-6,191
-22% -$854K 0.03% 555
2019
Q1
$4.33M Buy
28,730
+4,103
+17% +$590K 0.04% 415
2018
Q4
$3.06M Sell
24,627
-7,568
-24% -$1.03M 0.03% 481
2018
Q3
$5.1M Buy
32,195
+15,009
+87% +$2.27M 0.05% 362
2018
Q2
$2.41M Buy
17,186
+4,743
+38% +$651K 0.03% 587
2018
Q1
$1.65M Sell
12,443
-9,612
-44% -$1.31M 0.02% 691
2017
Q4
$2.75M Buy
22,055
+5,737
+35% +$709K 0.03% 484
2017
Q3
$2.02M Buy
16,318
+4,448
+37% +$526K 0.03% 536
2017
Q2
$1.35M Buy
+11,870
New +$1.28M 0.02% 666
2016
Q4
Sell
-11,764
Closed -$1.17M 1755
2016
Q3
$1.17M Buy
+11,764
New +$1.15M 0.02% 614
2016
Q2
Sell
-13,035
Closed -$1.14M 1629
2016
Q1
$1.14M Sell
13,035
-7,075
-35% -$623K 0.03% 519
2015
Q4
$2.27M Buy
+20,110
New +$2.17M 0.05% 322
2015
Q3
Sell
-27,744
Closed -$3.44M 1515
2015
Q2
$3.44M Buy
27,744
+1,612
+6% +$195K 0.1% 213
2015
Q1
$3.09M Buy
26,132
+7,349
+39% +$831K 0.09% 231
2014
Q4
$1.92M Sell
18,783
-17,451
-48% -$1.7M 0.06% 306
2014
Q3
$3.33M Buy
36,234
+20,638
+132% +$1.79M 0.1% 195
2014
Q2
$1.28M Buy
15,596
+64
+0.4% +$4.89K 0.04% 379
2014
Q1
$1.19M Buy
15,532
+5,755
+59% +$449K 0.05% 379
2013
Q4
$676K Buy
9,777
+1,921
+24% +$126K 0.03% 529
2013
Q3
$509K Buy
+7,856
New +$497K 0.02% 620

Other funds holding FBT

Cambridge Investment Research Advisors's FBT Position: Q1 2026 in Review

Cambridge Investment Research Advisors increased its First Trust NYSE Arca Biotechnology Index Fund (FBT) stake by 36% in Q1 2026, buying an estimated $2.87M and bringing the position to 52,054 shares worth $10.5M. The position accounts for 0.03% of the portfolio, ranked #602.

Cambridge Investment Research Advisors first reported a position in FBT in Q3 2013 and has held it in 47 quarters since. 307 funds tracked by Wall St. Rank hold FBT as of Q1 2026.

  • Cambridge Investment Research Advisors held 52,054 shares of First Trust NYSE Arca Biotechnology Index Fund worth $10.5M as of Q1 2026.
  • Cambridge Investment Research Advisors bought 13,893 First Trust NYSE Arca Biotechnology Index Fund shares in Q1 2026, an estimated $2.87M.
  • First Trust NYSE Arca Biotechnology Index Fund made up 0.03% of Cambridge Investment Research Advisors's portfolio in Q1 2026, its #602 holding.
  • Cambridge Investment Research Advisors first reported a position in First Trust NYSE Arca Biotechnology Index Fund in Q3 2013 and has held it in 47 quarters since.
  • 307 funds tracked by Wall St. Rank held First Trust NYSE Arca Biotechnology Index Fund as of Q1 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.